SCHEMBL6923005

SCHEMBL6923005

NCCCc1nc2cc(Br)ccc2c(=O)[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.48
CHEK1 O14757 2/20 0.46
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
PDE10A Q9Y233 1/20 0.43
KDM4E B2RXH2 2/20 0.42
RECQL P46063 1/20 0.42
PARP2 Q9UGN5 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
KDM4C Q9H3R0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16261141 0.86 PARP1 (0.66) PARP1NPC1RAB9APDE10AKDM4E
SCHEMBL19846637 0.85 PARP1 (0.60) PARP1NPC1RAB9AHDAC3HDAC4
SCHEMBL12058962 0.83 PARP1 (0.48) PARP1PDE10AKDM4ERECQLPARP2
SCHEMBL29136067 0.83 KDM4E (0.47) PARP1CHEK1NPC1RAB9APDE10A
SCHEMBL6922750 0.83 PARP1 (0.48) PARP1CHEK1NPC1RAB9APDE10A
SCHEMBL4973391 0.80 KDM4E (0.63) NPC1RAB9APDE10AKDM4ERECQL
SCHEMBL30186046 0.80 KDM4E (0.63) NPC1RAB9APDE10AKDM4ERECQL
SCHEMBL6791216 0.80 PARP1 (0.73) PARP1NPC1RAB9APDE10AKDM4E
SCHEMBL28279924 0.80 TNKS2 (0.62) PARP1NPC1RAB9AKDM4ERECQL
SCHEMBL6920370 0.80 NPC1 (0.46) PARP1NPC1RAB9APDE10AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 PARP1 3551/4885CHEK1 3301/4885NPC1 811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.